Literature DB >> 18077005

Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease.

Richard A O'Connor1, Stephen M Anderton.   

Abstract

The role of T regulatory (Treg) cells expressing the forkhead box transcription factor 3 (foxp3) in the control of autoaggressive immune responses is the subject of intense investigation. Here we explore the contribution of these cells to the regulation of experimental autoimmune encephalomyelitis (EAE). Starting from a historical perspective, we review their roles in preventing spontaneous disease, in setting the threshold for activation of a pathogenic response and in critically mediating the natural recovery from EAE. Current uncertainties and controversies are discussed in regard to EAE and multiple sclerosis as well as the potential for Treg-targeted immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18077005     DOI: 10.1016/j.jneuroim.2007.11.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  81 in total

1.  Histamine H4 receptor optimizes T regulatory cell frequency and facilitates anti-inflammatory responses within the central nervous system.

Authors:  Roxana del Rio; Rajkumar Noubade; Naresha Saligrama; Emma H Wall; Dimitry N Krementsov; Matthew E Poynter; James F Zachary; Robin L Thurmond; Cory Teuscher
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  Virus expanded regulatory T cells control disease severity in the Theiler's virus mouse model of MS.

Authors:  Maureen H Richards; Meghann Teague Getts; Joseph R Podojil; Young-Hee Jin; Byung S Kim; Stephen D Miller
Journal:  J Autoimmun       Date:  2011-01-26       Impact factor: 7.094

3.  Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.

Authors:  Daniel Larocque; Nicholas S R Sanderson; Josée Bergeron; James F Curtin; Joe Girton; Mia Wibowo; Niyati Bondale; Kurt M Kroeger; Jieping Yang; Liliana M Lacayo; Kevin C Reyes; Catherine Farrokhi; Robert N Pechnick; Maria G Castro; Pedro R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

4.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

5.  Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.

Authors:  C González-García; B Bravo; A Ballester; R Gómez-Pérez; C Eguiluz; M Redondo; A Martínez; C Gil; S Ballester
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 6.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

7.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

8.  Diazoxide attenuates autoimmune encephalomyelitis and modulates lymphocyte proliferation and dendritic cell functionality.

Authors:  N Virgili; P Mancera; C Chanvillard; A Wegner; B Wappenhans; M J Rodríguez; C Infante-Duarte; J F Espinosa-Parrilla; M Pugliese
Journal:  J Neuroimmune Pharmacol       Date:  2014-06-18       Impact factor: 4.147

Review 9.  Autoimmune T cell responses in the central nervous system.

Authors:  Joan Goverman
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

10.  Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

Authors:  Carl E Ruby; Melissa A Yates; Daniel Hirschhorn-Cymerman; Peter Chlebeck; Jedd D Wolchok; Alan N Houghton; Halina Offner; Andrew D Weinberg
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.